{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032512","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.664220+00:00","generated_at":"2026-05-17T01:06:17.233489+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Robert Ferrara resigns; David Deming appointed Lead Independent Director","bullets":["Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.","Board reduced from 6 to 5 members; no vacancies remain.","David Deming appointed Lead Independent Director; brings 30+ yrs investment banking (JP Morgan).","Deming joined Phio Board in Feb 2025; serves on Nominating Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032512","json":"https://secwatch.observer/filing/0001437749-25-032512.json","markdown":"https://secwatch.observer/filing/0001437749-25-032512.md","text":"https://secwatch.observer/filing/0001437749-25-032512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/0001437749-25-032512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/phio20251030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:06:17.233489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}